Germline Testing for Predisposition to Myeloid Malignancies (NCT07112287)

🧪 Interventions in This Study

• MyeloGen Gene Panel (DEVICE)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Dana-Farber Cancer Institute — Boston, Massachusetts

📞 Contact the Study Coordinator

Phone: (407) 443-6243

Email: Christopherr_reilly@dfci.harvard.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myeloid Malignancy

• Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms — Boston, Massachusetts
• Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories — Rochester, New York
• Pre-myeloid Cancer and Bone Marrow Failure Clinic Study — Scottsdale, Arizona
• Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies — Birmingham, Alabama
• A Telehealth Advance Care Planning Intervention — Rochester, New York

Explore by condition: All Myeloid Malignancy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.